CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akrivis Technologies, LLC announced today that it has reached a strategic alliance and distribution agreement with United States Biological Corporation, a world leader in the manufacture and distribution of antibodies and biochemicals used in research laboratories and production facilities. Adapting elements of nanotechnology with molecular detection and immunology, Akrivis Technologies has developed a modern solution to a long-standing research dilemma: how to provide aggressively lower sensitivity levels across multiple immunoassays and detection platforms, from colorimetric to fluorescent detection in vitro, to nuclear imaging in vivo.
